The Role of Gangliosides in the Repair of the Damaged Nervous System

Cajal SR Degeneration and regeneration of the nervous system. London: Oxford University Press, 1928.

LeGros Clarke WE The problem of neuronal regeneration in the central nervous system. II. The insertion of peripheral nerve stumps into the brain. J Anat 1943;77:251-258.

Dunn EH Primary and secondary findings in a series of attempts to transplant cerebral cortex in the albino rat. J Comp Neurol 1917 ;27:565-582.

Bjorklund A. , Stenevi U. Regeneration of monoaminergic and cholinergic neurons in the mammalian central nervous system. Physiol Rev 1979;59:62-100.

Robertson M. The unregenerate nervous system. Nature 1982;295:553-554.

Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237; 1154-1162.

Svennerholm L. Gangliosides and synaptic transmission. In: Svennerholm L , Mandel P , Urban P-F (eds.) Structure and function of gangliosides. New York: Plenum Press , 1980; 533-544.

Leon A. , Facci L. , Toffano G. , et al. Activation of (Na+, K+)ATPase by nanomolar concentrations of GM1 ganglioside. J Neurochem 1981;37:350-357.

Tettamanti G , Ledeen RW , Sandhoff K , Nagai Y , Toffano G (eds.), Gangliosides and neuronal plasticity. Padova: Liviana Press and Berlin: Springer Verlag , 1986. Fidia Research Series, vol 6.

Ledeen RW , Hogan EL , Tettamanti G , Yates AJ , Yu RK (eds.) New trends in ganglioside research. Padova : Liviana Press and Berlin : Springer Verlag, 1988. Fidia Research Series, vol 14.

Leon A. , Benvegnu D. , Dal Toso R. , et al. Dorsal root ganglia and nerve growth factor: a model for understanding the mechanism of GM1 effects on neuronal repair. J Neurosci Res 1984; 12:277-287.

Agnati LF , Fuxe K. , Calza L. , et al. Gangliosides increase the survival of lesioned nigral dopamine neurons and favor recovery of dopaminergic synaptic function in striatum of rats by collateral sprouting. Acta Physiol Scand 1983;119:347-363.

Sabel BA , Schneider GE Enhancement of sprouting of retinotectal fibers after early superior colliculus lesions in hamsters treated with gangliosides. Exp Brain Res 1988;71:365-376.

Li YS , Mahadik SP , Rapport MM , et al. Acute effects of GM1 ganglioside:Reduction in both behavioral asymmetry and loss of (Na+,K+)ATPase after nigrostriatal transection. Brain Res 1986;377:292-297.

Sabel BA , Stein DG Pharmacological treatment of central nervous system injury. Nature 1986;323:493.

Favaron M. , Manev H. , Guidotti A. , Costa E. Natural and semisynthetic sphingolipids protect neurons in culture from glutamate-induced toxicity. In: Biggio G , Spano PF , Toffano G , Gessa GL (eds.) Excitatory amino acids and brain ischemia. Oxford: Pergammon Press, 1990:93-102.

Vaccarino F. , Guidotti A. , Costa E. Ganglioside inhibition of glutamate-mediated protein kinase C translocation in primary cultures of cerebellar neurons. Proc Nat Acad Sci USA 1987;84:8707-8711.

Winegrad AL Does a common mechanism induce the diverse complications of diabetes? Diabetes 1987;36:396-406.

Bianchi R. , Berti-Mattera LN , Fiori MG , Eichberg J. Correction of altered metabolic activities in sciatic nerves of streptozotocin-induced diabetic rats: effect of ganglioside treatment. Diabetes 1990;39:782-788.

Norido F. , Canella R. , Zanoni R. , et al. The development of diabetic neuropathy in the C57BL/ks (db/db) mouse and its treatment with gangliosides. Exp Neurol 1984;83:221-232.

Norido F. , Canella R. , Gorio A. Ganglioside treatment of neuropathy in diabetic mice. Muscle and Nerve 1982; 5:107-110.

Triban C. , Guidolin D. , Fabris M. , et al. Ganglioside treatment and improved axonal regeneration capacity in experimental diabetic neuropathy. Diabetes 1989;38:1012-1022.

Gorio A. , Marini P. , Zanoni R. Muscle reinnervation. III Motoneuron sprouting capacity, enhancement by exogenous gangliosides. Neurosci 1983;8:417-429.

Norido F. , Canella R. , Aporti F. Acceleration of nerve regeneration by gangliosides estimated by somatosensory evoked potentials (SEP). Experientia 1981;37:301-302.

Fiori MG , Di Gregorio F , Fabris M. , et al. Processes of peripheral nerve and neuromuscularrepair. Annali dell Istituto Superiore di Sanita 1988 ;24:143-158.

Facci L. , Skaper SD , Presti D. , et al. Exogenously administered gangliosides fail to increase in vivo metastatic frequency or in vivo growth of murine neoplastic cells. Clin Exp Metastasis 1990;8:181-192.

Bacci B. , Figliomeni B. , Panozzo C. , et al. Favorable effects of ganglioside treatment on neurofibrillary pathology in beta, beta'-iminodipropionitrile (IDPN) intoxication. Neurosci Let 1988;suppl 22:S14.

Figliomeni B. , Bacci B. , Triban C. , et al. Beta, beta -iminodiproionitrile (IDPN)-induced axonopathy: effect of ganglioside treatment. Human Toxicology 1989;8:154 (Abstr.)

Purpura DP , Baker HJ Neurite induction in mature cortical neurones in feline GM I ganglioside storage disease. Nature 1977;266:553-554.

Toffano G. , Savoini GE , Moroni F. , et al. GM1 ganglioside stimulates the regeneration of dopaminergic neurons in the central nervous system. Brain Res 1983;241:143-144.

Gradkowska M. , Skup M. , Kiedrowski L. , et al. The effect of GM1 ganglioside on cholinergic and serotoninergic systems in the rat hippocampus following partial denervation is dependent on the degree of fibre degeneration . Brain Res 1986;375:417-422.

Karpiak SE Exogenous gangliosides enhance recovery from CNS injury. In: Ledeen RW , Yu RK , Rapport MM , Suzuki Y (eds.) Ganglioside structure, function and biomedical potential. London: Plenum Press, 1984;489-497.

Kojima H. , Gorio A. , Janigro D. , et al. GM1 ganglioside has a regrowth-enhancing effect on neurotoxin-induced lesion of noradrenaline nerve terminals in rat cerebral cortex. Neurosci 1984;13:1011-1022.

Aldinio C. , Calzolari S. , Rubini R. , et al. Intrahippocampal quinolinic acid injection and transneuronal degeneration: effects of GM1 ganglioside. Epilepsia 1985;26:516.

Janson AM , Agnati LF , Fuxe K. , et al. GM1 ganglioside protects against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol Scand 1988;32: 587-588.

Cahn J. , Borziex MG , Toffano G. Effect of GM1 ganglioside and its inner ester derivative in a model of transient cerebral ischemia in the rat. In: Tettamanti G , Ledeen RW , Sandhoff K , Nagai Y , Toffano G (eds.) Gangliosides and neuronal plasticity. Padova: Liviana Press and Berlin: Springer Verlag , 1986;435-443. Fidia research series, vol 6.

Borziex MG , Cahn R. , Cahn J. Effect of brain gangliosides on early and late consequences of a transient incomplete forebrain ischemia in the rat. Pharmacology 1989;38: 167-176.

Samson JC , Jack DB Monosialoganglioside (Sygen®; its role in CNS repair after injury. Drugs of Today 1990;26; 179-186.

Jack DB The therapeutic use of gangliosides. J Clin Pharm Ther 1990;15:233-239.

Stribling D. , Perkins CM , Smith JC , et al. Diabetic neuropathy and its treatment . Drugs of Today 1989;25:221-247.

Crepaldi G. Battistin L. , Bergamini L. , et al. Ganglioside treatment in diabetic peripheral neuropathy: a multicenter trial. Acta Diabetica Latina 1983;XX:265-276.

World Health Organization. Final report of peripheral investigators for WHO International Collaborative Study on Diabetic Peripheral Neuropathy. In: Scientific activities, WHO-OMS, Bull WHO 1985;63:655-656.

Adezati L. , Fonzo D. , D'Agnolo B. , et al. Attivita' e tollerabilita' del CRONASSIAL 50 mg/2 ml nelle neuropatie diabetiche. Studio clinico multicentrico controllato vs placebo . Medical Report, GL 904, January 18th, 1989.

Abraham RR , Whynn V. , Abraham RM A clinical trial of Cronassial in diabetic neuropathy. Report from the Alexander Simpson Laboratory for Metabolic Research, St. Mary's Hospital , London, dated April, 1983.

Naarden A. , Davidson J. , Harris L. , et al. Treatment of painful diabetic polyneuropathy with mixed gangliosides . In: Ledeen RW (ed.) Ganglioside structure, function and biomedical potential. New York : Plenum Press, 1983;581-592.

Horowitz SH Ganglioside therapy and diabetic neuropathy . Muscle and Nerve 1986;9:531-536.

Vaccari G. , Perri P. , Franchini A. , et al. Modificazione della soglia di sensabilita' retenica in pazienti diabetici prima e dopo trattamento con gangliosidi ad alti dosaggi. Annali Ottalmologia e Cliniche Oculistica 1987;113:977-1001.

Abraham RR , Levy DM , Abraham RM Changes in thermal sensation in diabetic patients after treatment with gangliosides . Diabetic Res 1988;7:129-135.

Liniger C. , Pernet A. , Moody JF , et al. Effect of gangliosides on diabetic peripheral neuropathy. Diabetes Res Clin Prac 1989;7:251-258.

Bacchieri A. , Ardia A. , Craveri A. II CRONASSIAL nel trattamento delle neuropatie diabetiche: confronto clinico di due schemi terapeutici. FIDIA statistical report. January 17, 1990.

Bacchieri A. , Ardia A. , Lingetti M. II CRONASSIAL nel trattamento delle neuropatie diabetiche: confronto clinico di due schemi terapeutici. FIDIA statistical report. January 15, 1990.

Kraemer G. , Suss W. , Kohler H. , et al. Gangliosid therapie der uraemischen polyneuropathie. Mediz Klin 1988;83:7-11.

Cubells JW , De Blas A. , Hernando C. , et al. Los gangliosidos de corteza cerebral bovina en el tratamiento de las lesiones radiculares. Medicos Clinicos 1980;75:156-160.

Franceschini G. , Ciaramella G. , Bassi P. , et al. Attivita' e tollerabilita' del CRONASSIAL 50mg/2 ml nelle lombosciatalgie. FIDIA research report, GL 901. 1989.

Di Marco C. , De Bastiani G. , Guida G. , et al. Attivita' e tollerabilita' del CRONASSIAL 50mg/2 ml nelle lombosciatalgie. FIDIA research report, GL 903. 1989.

Dainese R. , Brazzo F. , Caniato G. , et al. Verifica dell'efficacia terapeutica dei gangliosidi nel trattamento della polineurite periferica degli etilisti. La Clinica Terapeutica 1984;108: 305-312.

Hellman K. , Newton AK , Philips R. , et al. Pilot study on the antineuropathic effects of Cronassial in patients receiving vincristine. Department of Oncology and Neurology, Westminster Hospital, London. Report F110/5 CT5. September, 1986.

Fero Milone F. , Cananzi AR , D'Andrea G. , et al. Herpes Zoster. Trattamento con gangliosidi . Giornale Italiano di Ricerche Cliniche e Terapeutiche 1988;9:1-6.

Iosa D. , Massari DC Dorsey FC Chagas' cardioneuropathy: effect of ganglioside treatment in chronic dysautonomic patients—a randomized, double-blind, parallel, placebo-controlled study . Am Heart J 1991;122:775-785.

Battistin M. , Cesari A. , Galligioni F. , et al. Effects of GM1 ganglioside in cerebrovascular diseases: a double blind trial in 40 cases . Eur Neurol 1985;24:343-351.

Bassi S. , Albizzati MG , Sbacchi M. , et al. Monosialoganglioside therapy in stroke. Stroke 1985; 16:899-900.

Heiss WD Can PET estimate functional recovery and indicate therapeutic strategy in stroke? Proc 2nd Int Symp Pharm Cereb Ischaemia Marburg, 1988.

Argentino C. , Sacchetti ML , Toni D. , et al. GM 1 ganglioside therapy in acute stroke. Stroke 1989;20: 1143-1149.

Monaco P. , Pastore L. , Cottone S. , et al. Effect of early treatment with GM1 on neurological impariment during ischemic stroke. J Neurol 1991;238:120.

Carolei A. , Fieschi C. , Bruno R. , Toffano G. Monosialoganglioside, GM1, in cerebral ischemia. Cerebrovasc Brain Met Rev 1991;3:134-157.

Geisler FH , Dorsey FC , Coleman WP Recovery of motor function after spinal-cord injury—a randomized, placebo-controlled trial with GM1 ganglioside. NEJM 1991;324:1829-1838.

Hoermann M. Efficacy and safety of ganglioside GM1 treatment in the rehabilitation of patients following closed head traumatic injury. Results of an interim evaluation . In: Ledeen RW , Hogan EL , Tettamanti G , Yates AJ , Yu RK (eds.) New trends in ganglioside research:neurochemical and neuroregenerative aspects. Padova: Liviana Press and Berlin: Springer Verlag, 1988;595-604. Fidia Research Series, vol 14.

Geisler FH , Kantor D. GM1 gangliosides in the treatment of spinal cord injury: report of data analysis and results. In: Progressi di Diagnosi e Terapia. I Tumori Primitivi del Midollo Spinale (Oct 7-8 Torino ), 1988.